{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:54:41Z","timestamp":1765382081484,"version":"3.37.3"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191455","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T18:40:07Z","timestamp":1516905607000},"page":"e0191455","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-7716","authenticated-orcid":true,"given":"Aimee R.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"ref1","first-page":"453","article-title":"World Cancer Report","author":"P Humphrey","year":"2014"},{"issue":"S12","key":"ref2","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"BI Carlin","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00007-1","article-title":"Costs of prostate cancer, metastatic to the bone, in the Netherlands","volume":"43","author":"M Groot","year":"2003","journal-title":"European urology"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"F Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"9768","key":"ref5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"K Fizazi","year":"2011","journal-title":"The Lancet"},{"issue":"Suppl 2","key":"ref6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2010.10.007","article-title":"Examining the metastatic niche: targeting the microenvironment","volume":"37","author":"T Guise","year":"2010","journal-title":"Seminars in oncology"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-10-1040","article-title":"AACR centennial series: the biology of cancer metastasis: historical perspective","volume":"70","author":"JE Talmadge","year":"2010","journal-title":"Cancer research"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/pros.21277","article-title":"Dickkopf\u20141 (DKK\u20141) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases","volume":"71","author":"NK Thudi","year":"2011","journal-title":"The Prostate"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/en.2004-1211","article-title":"Bone turnover mediates preferential localization of prostate cancer in the skeleton","volume":"146","author":"A Schneider","year":"2005","journal-title":"Endocrinology"},{"issue":"22","key":"ref10","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor \u03baB Fc diminishes prostate cancer progression in bone","volume":"63","author":"J Zhang","year":"2003","journal-title":"Cancer Research"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer\u2013induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"J Zhang","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"9","key":"ref12","first-page":"2096","article-title":"Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice","volume":"63","author":"H Yonou","year":"2003","journal-title":"Cancer Research"},{"issue":"9810","key":"ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"MR Smith","year":"2012","journal-title":"The Lancet"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"ref15","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0. The Cochrane Collaboration. 2011."},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"MR Smith","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/14750708.5.1.63","article-title":"Osteoclast-targeted therapy for metastatic prostate cancer","volume":"5","author":"RJ Lee","year":"2008","journal-title":"Therapy"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"DP Dearnaley","year":"2009","journal-title":"The Lancet Oncology"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2014results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"MD Mason","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","article-title":"Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial","volume":"15","author":"JW Denham","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"M Wirth","year":"2015","journal-title":"European Urology"},{"issue":"10024","key":"ref22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"ND James","year":"2016","journal-title":"The Lancet"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1470-2045(12)70423-0","article-title":"Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial","volume":"13","author":"JW Denham","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"30","key":"ref24","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis\u2013free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"MR Smith","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"R Baron","year":"2011","journal-title":"Bone"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"R Coleman","year":"2012","journal-title":"Journal of the National Cancer Institute"},{"issue":"13","key":"ref27","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.1331931100","article-title":"From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression","volume":"100","author":"O Schmidt-Kittler","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/0008-5472.CAN-10-3922","article-title":"CD8+ T cells regulate bone tumor burden independent of osteoclast resorption","volume":"71","author":"K Zhang","year":"2011","journal-title":"Cancer research"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","article-title":"Bisphosphonates&apos; antitumor activity: an unravelled side of a multifaceted drug class","volume":"48","author":"P Cl\u00e9zardin","year":"2011","journal-title":"Bone"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2013a systematic review","volume":"62","author":"A de Groot","year":"2018","journal-title":"Cancer Treatment Reviews"},{"issue":"7335","key":"ref31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling","volume":"470","author":"W Tan","year":"2011","journal-title":"Nature"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.20131889","article-title":"Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance","volume":"211","author":"IS Khan","year":"2014","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"CL Vale","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"CS Col\u00f3n\u2014Emeric","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"Suppl 1","key":"ref35","article-title":"The Effect of Bisphosphonates on All-Cause and Post-Fracture Mortality Risk in the Population-based Canadian Multicentre Osteoporosis Study (CaMOS)","volume":"31","author":"D Bliuc","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"RE Coleman","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"T Chen","year":"2002","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"D Amadori","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/1097-0142(19941101)74:9<2533::AID-CNCR2820740922>3.0.CO;2-D","article-title":"Identification of bone marrow micrometastases in patients with prostate cancer","volume":"74","author":"D Wood Jr","year":"1994","journal-title":"Cancer"},{"key":"ref40","first-page":"1","article-title":"Comparison of hybrid 68Ga-PSMA-PET\/CT and 99mTc-DPD-SPECT\/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT","author":"J-C Janssen","year":"2017","journal-title":"European Radiology"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ph10030068","article-title":"Assessment of Bone Metastases in Patients with Prostate Cancer\u2014A Comparison between 99mTc-Bone-Scintigraphy and [68Ga] Ga-PSMA PET\/CT","volume":"10","author":"L Thomas","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"FE Lecouvet","year":"2012","journal-title":"European Urology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:55:17Z","timestamp":1588996517000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191455"}},"subtitle":[],"editor":[{"given":"Adriano","family":"Angelucci","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191455","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}